4.8 Article

Integrated Photothermal-Pyroelectric Biosensor for Rapid and Point-of-Care Diagnosis of Acute Myocardial Infarction: A Convergence of Theoretical Research and Commercialization

Journal

SMALL
Volume 18, Issue 30, Pages -

Publisher

WILEY-V C H VERLAG GMBH
DOI: 10.1002/smll.202202564

Keywords

acute myocardial infarction; cascade enzyme amplification; point-of-care; pyroelectric biosensors

Funding

  1. National Natural Science Foundation of China [21874022, 21675029]

Ask authors/readers for more resources

This study reports the development of a dual-mode photothermal-pyroelectric output system for rapid detection of acute myocardial infarction (AMI). The method utilizes cascade enzymatic amplification to convert the target signal into a thermal and pyroelectric signal, allowing sensitive detection of cTnI protein in whole blood. The integrated digital bio-testing platform shows excellent stability and ultra-low detection limit for the target protein.
Acute myocardial infarction (AMI) survivors face a high risk of mortality as a result of increasing heart failure and irreparable myocardial injury. New portable methods for immediate diagnosis must be developed to provide patients with daily warnings. Herein, the development of a dual-mode photothermal-pyroelectric output system based on a point-of-care platform for rapid AMI detection is reported. Termed as Integrated Photothermal-Pyroelectric Biosensor for AMI (IPPBA), the method leverages cascade enzymatic amplification to convert the target signal into a thermal and pyrooelectric conversion of the testing process by delicate pyroelectric pervokite NaNbO3 nanocubes modified microelectrodes for sensitive detection of cTnI protein in whole blood. In addition, the mechanism of the proposed pyroelectric bioassay model is explored in depth based on in situ variable temperature X-ray diffraction (XRD) lattice change statistics and density function theory (DFT) calculations. With standard samples and under optimized experimental conditions, the proposed IPPBA platform exhibits excellent signal stability and ultra-low detection limit (0.05 ng mL(-1)) for the target cTn I. With further developments in digital technology (e.g., 5G signaling protocols, fully automated systems), the integrated digital bio-testing platform IPPBA is fully capable of accomplishing positive and timely diagnosis of AMI.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available